Description: Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Home Page: www.geminalabs.com
3600 Gilmore Way
Burnaby,
BC
V5G 4W8
Canada
Phone:
604-760-1997
Officers
| Name | Title |
|---|---|
| Mr. Brian Firth | CEO & Director |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | CFO & Company Secretary |
| Dr. Robert Crandall Greene | CTO & Director |
| Mr. Hugh McNaught | VP of Marketing & Member of Advisory Board |
| Mr. David Browning FCIM, M.Sc. | Head of Productization & Director of Gemina Laboratories (UK) Limited |
| Dr. Christine Buerki Ph.D. | Head of Product Development |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 343.9577 |
| Price-to-Sales TTM: | 5789.8237 |
| IPO Date: | |
| Fiscal Year End: | January |
| Full Time Employees: | 0 |